Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy.

ABSTRACT:

Backgroud

Recent trials suggest sodium-glucose cotransporter 2 inhibitors (SGLT2i) significantly reduced proteinuria in patients with IgA nephropathy (IgAN). While little was known its efficacy in clinical practice especially in those already received full dose reninangiotensin-aldosterone system (RAAS) inhibitors.

Methods

A cohort of 93 Chinese patients with biopsy-proven IgAN and persistent proteinuria underwent full supportive therapy, including optimal blood pressure control and full dose angiotensin-converting enzyme-inhibitor or angiotensin receptor blocker therapy. Proteinuria reduction at three and six months after initiating SGLT2i therapy was analyzed.

Results

A total of 93 patients were enrolled in this study and 62 of them completed the six-month follow-up

SUBMITTER: Dong Y 

PROVIDER: S-EPMC10509766 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature